Robson ME, Im SA, Senkus E, Xu B, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus
chemotherapy treatment of physician's choice in patients with a germline BRCA
mutation and HER2-negative metastatic breast cancer. Eur J Cancer 2023;184:39-47.
PMID: 36893711